- Home
- CUB vs ETON Comparison
CUB vs ETON Comparison
Compare CUB & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUB
- ETON
- Stock Information
- Founded
- CUB 2024
- ETON 2017
- Country
- CUB United States
- ETON United States
- Employees
- CUB N/A
- ETON N/A
- Industry
- CUB
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- CUB
- ETON Health Care
- Exchange
- CUB NYSE
- ETON Nasdaq
- Market Cap
- CUB 322.0M
- ETON 388.3M
- IPO Year
- CUB 2024
- ETON 2018
- Fundamental
- Price
- CUB $10.49
- ETON $14.85
- Analyst Decision
- CUB
- ETON Strong Buy
- Analyst Count
- CUB 0
- ETON 3
- Target Price
- CUB N/A
- ETON $29.67
- AVG Volume (30 Days)
- CUB 48.5K
- ETON 621.3K
- Earning Date
- CUB 08-22-2025
- ETON 08-07-2025
- Dividend Yield
- CUB N/A
- ETON N/A
- EPS Growth
- CUB N/A
- ETON N/A
- EPS
- CUB 0.34
- ETON N/A
- Revenue
- CUB N/A
- ETON $48,327,000.00
- Revenue This Year
- CUB N/A
- ETON $103.21
- Revenue Next Year
- CUB N/A
- ETON $51.34
- P/E Ratio
- CUB $31.16
- ETON N/A
- Revenue Growth
- CUB N/A
- ETON 40.88
- 52 Week Low
- CUB $9.96
- ETON $3.25
- 52 Week High
- CUB $10.61
- ETON $21.48
- Technical
- Relative Strength Index (RSI)
- CUB N/A
- ETON 54.31
- Support Level
- CUB N/A
- ETON $13.78
- Resistance Level
- CUB N/A
- ETON $16.27
- Average True Range (ATR)
- CUB 0.00
- ETON 0.83
- MACD
- CUB 0.00
- ETON 0.32
- Stochastic Oscillator
- CUB 0.00
- ETON 77.67
About CUB LIONHEART HOLDINGS
Lionheart Holdings is a blank check company.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.